Endoscopic ultrasound versus endoscopic retrograde cholangiopancreatography for primary palliation of malignant distal biliary obstruction: a cost–effectiveness modeling analysis
Endoscopy · 01.09.2026 · 58 (09) · 963-974
DOI: 10.1055/a-2837-1405 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Endoscopy, erschienen am 01.09.2026. Verfasst von Patrick T Magahis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Brigham and Women's Hospital, Department of Medicine, Massachusetts, United States, Boston. Hauptthemen laut MEDLINE: Palliative Care, Endosonography, Cholangiopancreatography, Endoscopic Retrograde, Cholestasis.
Abstract (Originalsprache)
Background
Endoscopic retrograde cholangiopancreatography-guided transpapillary biliary drainage (ERCP-BD) is the standard for primary palliation of malignant distal biliary obstruction (MDBO), but endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS) has demonstrated improved technical success, efficiency, and safety in randomized trials. However, cost-effectiveness data are lacking. In this modeling study, we analyzed the cost-effectiveness of EUS-CDS with lumen-apposing metal stent (LAMS) and ERCP-BD with self-expandable metal stent (SEMS) for primary MDBO palliation.
Methods
A state-transition Markov model compared EUS-CDS and ERCP-BD over a 1-year time horizon from a US healthcare perspective. The base case was a 70-year-old with locally advanced, unresectable pancreatic cancer, common bile duct dilation >15 mm, and MDBO. Probabilities were derived from meta-analyses of randomized trials. Outcomes were incremental cost-effectiveness ratios (ICERs), with a willingness-to-pay (WTP) threshold of $100 000/quality-adjusted life year (QALY). Extensive sensitivity analyses were performed.
Results
EUS-CDS with LAMS was cost effective versus ERCP-BD with SEMS for primary treatment of MDBO at an ICER of $47 711/QALY. In one-way sensitivity analyses, EUS-CDS remained cost effective if it cost $11 174. ERCP-BD would become cost effective if technical success was >91%, reintervention
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Brigham and Women's Hospital, Department of Medicine, Massachusetts, United States, Boston.
- New York-Presbyterian Hospital/Weill Cornell Medicine, Division of Gastroenterology and Hepatology, New York, United States, New York.
- Medical University of South Carolina, Division of Gastroenterology and Hepatology, South Carolina, United States, Charleston.
- Johns Hopkins Hospital, Division of Gastroenterology and Hepatology, Maryland, United States, Baltimore.
ORCID-Profile: Patrick T Magahis, Reem Z Sharaiha
Zitieren
APA
Magahis, P. T., Mahadev, S., Elmunzer, B. J., Khashab, M. A., Hanscom, M., Sampath, K., Carr-Locke, D. L., & Sharaiha, R. Z. (2026). Endoscopic ultrasound versus endoscopic retrograde cholangiopancreatography for primary palliation of malignant distal biliary obstruction: a cost–effectiveness modeling analysis. Endoscopy, 58(09), 963-974. https://doi.org/10.1055/a-2837-1405
Vancouver
Magahis PT, Mahadev S, Elmunzer BJ, Khashab MA, Hanscom M, Sampath K, et al. Endoscopic ultrasound versus endoscopic retrograde cholangiopancreatography for primary palliation of malignant distal biliary obstruction: a cost–effectiveness modeling analysis. Endoscopy. 2026;58(09):963-974. doi:10.1055/a-2837-1405
BibTeX
@article{Magahis2026,
author = {Magahis, Patrick T and Mahadev, SriHari and Elmunzer, Badih Joseph and Khashab, Mouen A and Hanscom, Mark and Sampath, Kartik and Carr-Locke, David L and Sharaiha, Reem Z},
title = {Endoscopic ultrasound versus endoscopic retrograde cholangiopancreatography for primary palliation of malignant distal biliary obstruction: a cost–effectiveness modeling analysis},
journal = {Endoscopy},
year = {2026},
volume = {58},
number = {09},
pages = {963--974},
doi = {10.1055/a-2837-1405}
}
EUVIMED